

Cutaneous Squamous Cell Carcinoma



Vishwas Parekh, MD^a, John T. Seykora, MD, PhD^{b,*}

KEYWORDS

- Squamous cell carcinoma • Actinic keratosis • Keratoacanthoma
- Spindle cell squamous cell carcinoma • Desmoplastic squamous cell carcinoma
- Acantholytic squamous cell carcinoma • Pathogenesis

KEY POINTS

- There is a persistent trend for an increasing incidence of cutaneous squamous cell carcinoma (cSCC).
- It is crucial to differentiate cSCC from the benign and reactive squamoproliferative lesions and report the high-risk features associated with an aggressive tumor behavior.
- Understanding the molecular mechanisms that drive the development and progression of cSCC is necessary to develop diagnostic and prognostic assays and targeted therapies.

INTRODUCTION

Epidemiology

Nonmelanoma skin cancer is the most common malignancy worldwide. Historically, cutaneous squamous cell carcinoma (cSCC) has been thought to comprise about 20% of all nonmelanoma skin cancers, thus being the second most common malignancy after basal cell carcinoma (BCC), with a ratio of BCC to SCC estimated to be 4:1.^{1,2} However, recent data indicate that there is a significant shift underway in the relative proportion of nonmelanoma skin cancer, with the ratio of BCC to SCC found to be 1.0 in the US Medicare population.³ Several other studies bear out a trend for an increasing incidence of cSCC compared with BCC, particularly in the aging population.⁴⁻⁸ An accurate incidence of cSCC is not known because it is not required to be reported to national cancer registries; however, a metaanalysis of population-based studies estimated that in 2012, 186,157 to 419,543 white individuals were diagnosed with cSCC in the United States alone. Note, these estimates do not include squamous cell carcinoma in situ (SCCIS), which likely occurs more frequently.⁹

^a Department of Pathology, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA, 91010, USA; ^b Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Room 1011 BRB II/III, 421 Curie Boulevard, Philadelphia, PA 19104, USA

* Corresponding author.

E-mail address: john.seykora@uphs.upenn.edu

Clin Lab Med 37 (2017) 503–525

<http://dx.doi.org/10.1016/j.cl.2017.06.003>

0272-2712/17/© 2017 Elsevier Inc. All rights reserved.

labmed.theclinics.com

Etiopathogenesis

Most cSCC arise in the sun-damaged skin of the elderly white individuals of European ancestry, in the background of preexisting lesions of actinic keratosis (AK).¹ Apart from ultraviolet (UV) radiation exposure, other predisposing factors include chronic immunosuppressed state (solid organ transplantation, human immunodeficiency virus infection),^{10–13} chronic skin conditions (burn scars, hidradenitis suppurativa, chronic osteomyelitis, discoid lupus erythematosus, lichen plans, lichen sclerosus et atrophicus),^{14–20} inherited genetic conditions (albinism, epidermolysis bullosa, xeroderma pigmentosum),^{21–23} exposure to ionizing radiation,²⁴ chronic arsenic exposure,²⁵ human papillomavirus infection,^{26,27} and treatment with BRAF inhibitors (vemurafenib and dabrafenib),²⁸ among others.

Clinical Features

AK and SCCIS are considered to be the precursor lesions of cSCC in most instances, and, frequently, patients present with cSCC in association with numerous precursor lesions. AK and SCCIS typically present as flesh-colored, pink, brown, often pigmented, scaly patches, papules, or plaques on an erythematous base. Lesions of cSCC manifest a range of clinical presentations, including papules, plaques, or indurated nodules with a smooth, scaly, verrucous, or ulcerative surface. Cutaneous SCC can be asymptomatic, pruritic, or tender. Local neuropathic symptoms such as numbness, burning, paresthesia, or paralysis are associated with perineural invasion.²⁹ Although cSCC typically arises on the sun-exposed areas of fair-skinned individuals and often on the sun-exposed areas of dark-skinned individuals, an involvement of the non-sun-exposed areas is more common in dark-skinned individuals.^{30,31}

PRECURSOR LESIONS

Actinic Keratosis

Also known as solar keratosis, AK represents an early precursor lesion that can accumulate additional mutations and in some cases progress to SCCIS and invasive SCC.³² Clinically, AKs often manifest spontaneous regression and approximately one-third of AKs exhibit regression in 1 year.³³

Histologically, AK occurs as a proliferation of cytologically atypical keratinocytes that is confined to the lower levels of the epidermis. The lesional cells show loss of polarity, increased size, pleomorphic and hyperchromatic nuclei, and an increased number of mitoses. There is often an increased nuclear:cytoplasmic ratio within lesional cells. There is crowding of the basal portion of the epidermis with variable acanthosis and/or budding of the neoplastic keratinocytes in the papillary dermis, without breach of the basement membrane. By definition, the atypical proliferation does not occupy the full thickness of the epidermis. Hypogranulosis is often seen. The stratum corneum overlying the atypical keratinocytes typically shows hyperkeratosis with parakeratosis. Because the preneoplastic process usually spares the adnexal structures, this results in alternating areas of orthokeratosis and parakeratosis (flag sign). The underlying dermis almost invariably shows solar elastosis, which represents an important diagnostic clue. AKs exhibit a variety of histologic variants with a broad range of histologic patterns.^{34,35}

Pigmented actinic keratosis

This variant shows hyperpigmentation of the lower epidermal layers owing to an increased amount of melanin in the basilar keratinocytes. Melanophages may be present in the superficial dermis. It is important to recognize this entity because it can be

confused clinically, as well as histologically, with melanoma in situ, particularly in the presence of severe solar elastosis. There may be mild melanocytic hyperplasia of melanocytes typical of that seen in sun-damaged skin. Melanocytes in these lesions do not manifest cytologic atypia. Immunohistochemistry with melanocytic markers is useful in difficult cases.

Lichenoid actinic keratosis

This variant is characterized by a dense, bandlike lymphocytic infiltrate at the dermal-epidermal junction with focal vacuolar alteration and necrosis of the basal keratinocytes. This entity may be confused morphologically with benign lichenoid keratosis and lichenoid regression in melanoma.

Bowenoid actinic keratosis

In this variant, the atypical keratinocytes occupy almost the full thickness of epidermis and yet do not reach the level of SCCIS. There may be palisading in the basal layer. The adnexal sparing character of AK is often helpful in distinguishing this variant from SCCIS or Bowen's disease.

Proliferative actinic keratosis

In this variant, atypical keratinocytes extend fingerlike projections in the superficial dermis. Examination of multiple, deeper level sections is often helpful in allaying a concern for superficial invasion. This variant is associated with a more aggressive behavior.³⁶

Hypertrophic actinic keratosis

This variant demonstrates epidermal hyperplasia with a prominent hyperparakeratotic stratum corneum. Often, the epidermal changes suggestive of a superimposed lichen simplex chronicus are also present.

Atrophic actinic keratosis

This variant shows atrophic changes in the form of thinned out epidermis and flattened rete ridges.

Acantholytic actinic keratosis

This variant is characterized by acantholysis of atypical keratinocytes resulting in detachment from each other and intraepidermal clefting. Dyskeratosis may be present. The differential diagnosis includes benign acantholytic disorders.

Squamous Cell Carcinoma In Situ

SCCIS occupies the intermediate step in the progression from AK to invasive SCC. Although some use SCCIS and Bowen's disease terminology interchangeably, Bowen's disease typically occurs in the anogenital region and is unrelated to UV-induced AK and more often associated with human papillomavirus infection, thus being more common in young adults.³⁷

Histologically, SCCIS exhibits full-thickness atypia of the epidermis, sparing the adnexal structures. The hyperparakeratosis can be minimal or exuberant and can produce a cutaneous horn. The atypical keratinocytes show nuclear pleomorphism, hyperchromasia, frequent mitoses with atypical forms, and apoptosis. The loss of polarity imparts a "windblown" appearance. Frequently, the atypical keratinocytes spare the basal layer and produce a characteristic pattern called the "eyeliner sign," a useful diagnostic clue observable on a low-power examination. By definition, there is no dermal invasion. Similar to AK, several histomorphologic variants of SCCIS have been described, including hyperkeratotic, atrophic, verrucous, psoriasiform,

acantholytic, clear cell, and pagetoid subtypes. It is important to histologically distinguish the pagetoid variant of SCCIS from extramammary Paget's disease and melanoma in situ. Immunohistochemical (IHC) markers such as CK7, CAM5.2, carcinoembryonic antigen, and epithelial membrane antigen (positive in extramammary Paget's disease, negative in SCCIS), p63 (positive in SCCIS, negative in extramammary Paget's disease), and MART1 (positive in melanoma in situ) are helpful in diagnosing difficult cases.^{38,39}

INVASIVE CUTANEOUS SQUAMOUS CELL CARCINOMA

Cutaneous SCC can arise as the result of tumor progression in the sun-damaged skin or can occur de novo. It is characterized by invasion of the dermis by the neoplastic squamous epithelial cells. The invasive component can take the form of infiltrating cords, sheets, or single cells, or can present as well-circumscribed nodules, squamous islands, or cystic structures composed of malignant keratinocytes. Interestingly, in contrast with AK and SCCIS, the cytomorphology of malignant keratinocytes in cSCC can vary from a very banal appearance to a highly anaplastic one.^{40,41}

Histologic Grading

Lesions of cSCC can be histologically divided into 3 grades based on their degree of differentiation: well, moderately, and poorly differentiated. The factors taken into consideration for this type of grading include the degree of keratinization, nuclear atypia, and the degree of architectural atypia (well circumscribed vs infiltrative).

A well-differentiated cSCC shows slightly enlarged keratinocytes with abundant, glassy-pink to eosinophilic cytoplasm. Intercellular bridges are generally visible. Keratinization is usually present and morphologically manifests as a central plug of keratinization within a nest of well-differentiated keratinocytes, commonly referred to as a "keratin pearl." Importantly, identifying the retention of keratinocyte nuclei (parakeratosis) within these keratin pearls is often useful in discriminating a well-differentiated cSCC from a benign squamoproliferative lesion in a superficial biopsy. Well-differentiated cSCC tends to be well-circumscribed with pushing margins and a lobulated appearance. In contrast, a poorly differentiated cSCC shows a highly infiltrative pattern and is composed of highly atypical keratinocytes with pleomorphic, hyperchromatic nuclei, numerous atypical mitotic figures, and shows little or no keratinization.^{40,42} (Fig. 1).

Histologic Variants

Several histologic variants of cSCC have been described. Knowledge of these entities has diagnostic and prognostic significance.

Acantholytic squamous cell carcinoma

This variant is also known as adenoid SCC, adenoacanthoma of sweat glands, and pseudoglandular SCC. Rare subtypes such as small cell SCC, pseudovascular SCC, and pseudoangiosarcomatous SCC have been described. Histologically, the lesional cells show a variable degree of desmosomal disruption, resulting in rounded cells with centrally placed round nuclei. Acantholysis results in various morphologic patterns, such as pseudoglandular, pseudoalveolar, or pseudovascular spaces. Based on their involvement of the follicular epithelium alone or involvement of follicular epithelium and interfollicular epidermis, these tumors have also been further subdivided as the follicular type and follicular pattern, respectively.^{42–47} (Fig. 2A).

The differential diagnoses for acantholytic SCC include adenoid BCC, eccrine carcinoma, metastatic adenocarcinoma, and, rarely, angiosarcoma. Identifying




Fig. 1. Squamous cell carcinoma. (A) Well-differentiated. The tumor shows nests of mature keratinocytes with a low nuclear:cytoplasmic ratio and “keratin pearls” (original magnification, $\times 200$), (B) Moderately differentiated. The tumor shows cellular pleomorphism, few, if any, keratin pearls and cells with more prominent cellular atypia (original magnification, $\times 400$). (C) Poorly differentiated. The tumor shows infiltrative pattern and highly atypical keratinocytes with pleomorphic, hyperchromatic nuclei, and little to no keratinization (original magnification, $\times 400$).

characteristic areas with basaloid cells, peripheral palisading, single cell necrosis, artifactual clefting, and stromal mucin would help to distinguish the adenoid BCC. Identifying ductal structures with a basal or myoepithelial layer that stains for smooth muscle actin, p63, calponin, or S100 protein, luminal borders that stain for carcinoembryonic antigen, and luminal secretions that stain with periodic acid–Schiff distase help to distinguish the eccrine carcinoma. Metastatic adenocarcinoma can be suspected from the clinical history, a multiplicity of lesions, and a lack of epidermal connection. Use of high- and low-molecular-weight cytokeratin antibodies and a battery of immunostains specific for adenocarcinomas from various sites of origin are essential in arriving at the correct diagnosis. Angiosarcoma can be suspected from blood-filled spaces and confirmed with various endothelial markers such as CD31, CD34, and ERG.

Adenosquamous carcinoma

This rare variant of cSCC is characterized by true glandular differentiation, in contrast with the pseudoglandular appearance seen in the acantholytic SCC. Histologically, the atypical squamoid cells are arranged as interconnecting nests, frequently forming keratocysts. Additionally, there are focal or diffuse areas of gland formation within the squamous nests. These glands are lined by cuboidal to low columnar epithelium that shows luminal positivity for carcinoembryonic antigen. The luminal secretions




Fig. 2. Squamous cell carcinoma. (A) Acantholytic. Desmosomal disruption results in clefting and rounding of the tumor cells (original magnification, $\times 200$). (B) Spindle cell. Haphazard growth of atypical spindle-shaped keratinocytes in the dermis. Inset: p63 immunostain confirms epithelial origin (original magnification, $\times 200$). (C) Desmoplastic. Infiltrating cords of spindled tumor cells surrounded by a densely collagenous stroma. Inset: p63 immunostain (original magnification, $\times 200$). (D) Signet ring cell. A variable number of tumor cells show clear cytoplasm that pushes the nucleus to the periphery imparting a signet ring appearance (original magnification, $\times 400$).

stain with mucicarmine and Alcian blue at a pH of 2.5. The epidermal origin is evidenced by multifocal epidermal connections. The tumor commonly invades the deep dermis.^{48–50}

The differential diagnosis for this variant includes primary cutaneous mucoepidermoid carcinoma and metastatic adenocarcinomas from various sites of origin. Primary cutaneous mucoepidermoid carcinoma is a controversial entity and, if it does exist, currently there is no reliable way to distinguish it from adenosquamous carcinoma.⁵¹ Distinction from metastatic adenocarcinomas requires a thorough clinical history and imaging studies to identify a primary site, the presence of multiple lesions, histologic demonstration of a lack of epidermal connection, and, when necessary, judicious use of IHC markers.

Spindle cell squamous cell carcinoma

This variant is also known as sarcomatoid SCC. Histologically, this tumor is characterized by a haphazard growth of atypical spindle-shaped cells in the dermis. Connection with the epidermis is not always present. The atypical spindle cells may constitute all or part of the tumor, with none or a variable component of conventional SCC forming nests, cords, and keratin pearls. Occasionally, bizarre and pleomorphic giant cells and heterologous elements with numerous mitotic figures are seen. The tumor often

infiltrates deep into the dermis, subcutis, fascia, muscle, and bone.⁵²⁻⁵⁴ Importantly, there is not significant stromal desmoplasia (>30% of the tumor volume), because that would raise the diagnosis of the desmoplastic variant of cSCC⁵⁵ (see Fig. 2B).

The differential diagnosis for this variant, in the absence of an epidermal connection or an obvious evidence of keratinization, is an atypical spindle cell lesion of the dermis. This would include spindle cell/desmoplastic melanoma, leiomyosarcoma, and atypical fibroxanthoma or undifferentiated pleomorphic sarcoma, among other reactive and neoplastic dermal spindle cell proliferations. The use of the IHC markers is often required to derive a definitive diagnosis. Spindle cell SCC stains positively for p63, p40, and high-molecular-weight cytokeratins such as CK5/6.^{56,57} Desmoplastic melanoma stains for S100 protein and SOX10, and leiomyosarcoma stains for smooth muscle actin and caldesmon.

Desmoplastic squamous cell carcinoma

Histologically, this variant is characterized by infiltrating cords of spindled–squamoid tumor cells surrounded by a densely collagenous (desmoplastic) stroma. In contrast with spindle cell SCC, the lesional squamous cells are oval to spindle shaped and can show single-cell keratinization. Keratin pearls are generally present, even in high-grade tumors, and the desmoplastic stromal component in this tumor should constitute greater than 30% of the tumor volume. Perineural invasion is frequent with this variant^{55,58,59} (see Fig. 2C).

The differential diagnoses for this variant are entities that show sclerotic, desmoplastic stromal response with resultant infiltrative appearance. These include syringoma, desmoplastic trichoepithelioma, microcystic adnexal carcinoma, morpheaform BCC, and desmoplastic melanoma. The presence of epidermal squamous atypia and evidence of keratinization point to the diagnosis of desmoplastic SCC. Ductal differentiation points to the diagnoses of adnexal neoplasms. A diagnosis of morpheaform BCC would require identifying the typical findings of BCC, such as individual cell necrosis, mitotic figures and stromal retraction artifact in at least a focal manner. Additionally, the tumor cords in morpheaform BCC show sharp angulation that is quite characteristic. Desmoplastic melanoma is associated with the findings of in situ melanocytic lesion in the overlying epidermis and nodular lymphoid aggregates within the dermal component. Use of p63 (positive in SCC) and S100 and SOX10 (positive in desmoplastic melanoma) is helpful in difficult cases.

Clear cell squamous cell carcinoma

Also referred to as hydropic SCC or pale cell SCC, these rare tumors are subdivided into 3 categories: type I (keratinizing), type II (nonkeratinizing), and type III (pleomorphic). Type I tumors are characterized by sheets or islands of clear cells with peripherally displaced nuclei or central nuclei with bubbly cytoplasmic appearance, and focal areas of keratinization, even forming keratin pearls. Type II tumors are dermal masses without connection to the epidermis. Tumor cells show a cytoplasm with a finely reticulated clear appearance and are arranged in parallel or anastomosing cords separated by a fibrotic stroma with a heavy inflammatory infiltrate. There may be a central necrosis but, importantly, keratinization is absent. Type III tumors typically show extensive ulceration. Tumor cells are markedly pleomorphic with foci of acantholysis, dyskeratosis, keratinization, and perineural and lymphovascular invasion.^{42,60}

The histologic differential diagnosis for clear cell SCC is broad: clear cell acanthoma, trichilemmoma, trichilemmal carcinoma, clear cell hidradenoma, hidradenocarcinoma, sebaceous tumors, clear cell BCC, balloon cell nevus, balloon

cell melanoma, and metastatic renal cell carcinoma, among other entities with clear cell changes.⁶¹ A high index of suspicion, a thorough analysis of all histologic sections, and a judicious use of IHC markers are necessary to arrive at this diagnosis.

Signet ring cell squamous cell carcinoma

This is an extremely rare variant. Histologically, this tumor is composed of a variable number of signet ring cells, where a clear cytoplasm pushes the nucleus to the periphery imparting a signet ring appearance. The cytoplasm is negative for mucin and shows focal PAS positivity with diastase sensitivity^{62,63} (see **Fig. 2D**).

The differential diagnosis for this variant is extensive, because several primary cutaneous neoplasms such as BCC, melanoma, histiocytoid carcinoma of the eyelid, and lymphoproliferative diseases, as well as metastatic adenocarcinomas and soft tissue tumors can demonstrate signet ring cell changes. Once the signet ring cell changes are noted, identifying a focus of conventional SCC in the histologic sections in conjunction with IHC and special stains should promote derivation of the correct diagnosis.^{64,65}

Pigmented squamous cell carcinoma

This variant is characterized by a colonization of the conventional SCC by benign, heavily pigmented dendritic melanocytes. Histologically, the tumor is composed of lobules, nests, and cords of atypical squamous cells showing evidence of keratinization. Intermixed within the tumor cells are numerous darkly pigmented dendritic melanocytes that stain for melanocytic markers such as MART1, HMB45, and S100 protein, although HMB45 can be negative in rare cases. Rare focal positivity of the squamoid tumor cells for melanocytic markers is likely secondary to antigen transfer.^{66–68}

The histologic differential diagnosis for this variant includes other pigmented entities such as seborrheic keratosis, melanoacanthoma, pigmented trichoblastoma, pigmented pilomatricoma, pigmented BCC, melanoma with pseudoepitheliomatous hyperplasia, and an exceedingly rare dermal squamomelanocytic tumor.⁶⁹ Of these, the one tumor that is easy to be confused with pigmented SCC with potentially serious consequences is melanoma with pseudoepitheliomatous hyperplasia, where the malignant and benign components are transposed. A careful examination and identification of atypical melanocytes is essential to avoid this pitfall.

Verrucous carcinoma

This variant has a very distinctive silhouette owing to its endo-exophytic growth, and prominent acanthosis, papillomatosis, and hyperkeratosis. One key histologic feature is the blunt, broad, squamous epithelial projections that push into the dermis, rather than infiltrate the dermis. The tumor cells show a bland cytomorphology and the human papillomavirus-related cytopathic changes are not obvious. Rabbit burrow-like sinuses and keratocysts, and a dense inflammatory infiltrate are typically seen in carcinoma cuniculatum, a subtype of verrucous carcinoma localized to the plantar surface^{42,70,71} (**Fig. 3A**).

The histologic differential diagnosis for this variant includes condyloma acuminatum, verruca vulgaris, keratoacanthoma, prurigo nodularis, and pseudoepitheliomatous hyperplasia. Clinicopathologic correlation and the availability of adequate biopsy material that includes the base of the tumor are essential for arriving at the correct diagnosis.




Fig. 3. (A) Verrucous carcinoma. Blunt, broad-based, squamous epithelial projections that push, rather than infiltrate, into the dermis (original magnification, $\times 20$). (B) Keratoacanthoma. Dome-shaped nodule with a central keratin-filled crater (original magnification, $\times 20$).

Keratoacanthoma

KA commonly presents as a rapidly growing, solitary, dome-shaped nodule with a central keratin-filled crater. The fact that it undergoes spontaneous resolution has led to a decades-long debate and uncertainty over the classification of this lesion with views ranging from KA being a benign squamoproliferative lesion, a continuum between benign and malignant proliferation, to an outright cSCC that has the biological capacity to regress. We have incorporated this entity here to enable its recognition from conventional SCC. Several clinical variants of KA are recognized including giant KA, mucosal KA, subungual KA, keratoacanthoma centrifugum marginatum, and multiple KAs associated with Ferguson-Smith disease, generalized eruptive keratoacanthomas of Grzybowski, multiple familial keratoacanthoma of Witten and Zak, Muir-Torre syndrome, and subungual tumors associated with incontinentia pigmenti^{42,72–74} (see [Fig. 3B](#)).

Histologically, KAs are composed of mature-appearing keratinocytes that form a large, symmetric, exo-endophytic mass with a central crateriform invagination filled with a keratin plug. Typically, there is buttressing of the surrounding normal epidermis around the mass. The tumor cells have a characteristic pink, glassy cytoplasm and lack the pleomorphism and atypia seen in conventional SCC. Most KAs show scattered neutrophils and eosinophils, occasionally forming microabscesses. Perforating elastic fibers are a characteristic finding.⁷⁵ Mixed inflammatory infiltrate and small islands of tumor cells may be present in the underlying dermis, and the lesions lack infiltrative features. The histologic differential diagnosis for KA includes well-differentiated conventional SCC and pseudoepitheliomatous hyperplasia found in association with inflammatory or reactive conditions.

High-Risk Features

Although the vast majority of cSCCs are cured with complete excision, a subset of cSCCs with certain histologic and clinical features exhibits a significantly increased risk of local recurrence and metastasis, and resultant poorer prognosis.^{76–78} The incidence of regional or distant metastases is estimated to be as high as 2% to 6% in such cases.^{79,80} Several staging systems have been proposed to stratify the cSCC prognosis based on a number of known risk factors. These include the 2002 TNM staging system proposed by the American Joint Committee on Cancer,⁸¹ the revised American Joint Committee on Cancer and International Union Against Cancer staging systems,^{77,82} Brigham and Women's Hospital tumor staging system,⁸³ National Comprehensive Cancer Network guidelines⁸⁴ ([Table 1](#)), and European Organization for Research and Treatment of Cancer guidelines⁸⁵ ([Table 2](#)).

Table 1 National Comprehensive Cancer Network clinical practice guidelines, version 1.2017: risk factors for local recurrence or metastasis		
History and Physical Examination	Low Risk	High Risk
Location/size ^a	Area L <20 mm Area M <10 mm ^d	Area L ≥20 mm Area M ≥10 mm Area H ^e
Borders	Well defined	Poorly defined
Primary vs recurrent	Primary	Recurrent
Immunosuppression	(−)	(+)
Site of prior RT or chronic inflammatory process	(−)	(+)
Rapidly growing tumor	(−)	(+)
Neurologic symptoms	(−)	(+)
Pathology	Low Risk	High Risk
Degree of differentiation	Well or moderately differentiated	Poorly differentiated
Adenoid (acantholytic), adenosquamous (showing mucin production), desmoplastic, or metaplastic (carcinosarcomatous) subtypes	(−)	(+)
Depth ^{b,c} : Thickness or Clark level	<2 mm or I, II, III	≥2 mm or IV, V
Perineural, lymphatic, or vascular involvement	(−)	(+)

Area H = “mask areas” of face (central face, eyelids, eyebrows, periorbital, nose, lips [cutaneous and vermillion], chin, mandible, preauricular and postauricular skin/sulci, temple, ear), genitalia, hands, and feet. Area M = cheeks, forehead, scalp, neck, and pretibia. Area L = trunk and extremities (excluding pretibia, hands, feet, nail units, and ankles).

^a Must include peripheral rim of erythema.
^b If clinical evaluation of incisional biopsy suggests that microstaging is inadequate, consider narrow margin excisional biopsy.

^c A modified Breslow measurement should exclude parakeratosis or scale crust, and should be made from base of ulcer if present.

^d Location independent of size may constitute high risk.
^e Area H constitutes high risk based on location, independent of size. Narrow excision margins owing to anatomic and functional constraints are associated with increased recurrence rates with standard histologic processing. Complete margin assessment, such as with Mohs micrographic surgery, is recommended for optimal tumor clearance and maximal tissue conservation. For tumors less than 6 mm in size, without other high-risk features, other treatment modalities may be considered if at least 4-mm clinically tumor-free margins can be obtained without significant anatomic or functional distortions.

From Bichakjian CK, Farma JM, Schmults CD, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Squamous Cell Skin Cancer. Fort Washington (PA): National Comprehensive Cancer Network, Inc; 2016; with permission.

Clinical high-risk features

Tumor location Tumors arising in head and neck locations (eg, forehead, temporal region, scalp, lips, ears) show increased rates of local recurrence and metastasis.^{79,86,87} A recent metaanalysis showed that the anatomic locations of lips, ears, and temple are independent predictors of metastasis, although, in this analysis, tumor location on lips or ears did not independently predict local recurrence.⁸⁸ Additionally, tumors developing in chronic wounds or scars or at the site of prior burns or radiation therapy

Table 2
European Organization for Research and Treatment of Cancer Guidelines: prognostic risk factors in primary cutaneous squamous cell carcinoma

	Tumor Diameter	Location	Depth/Level of Invasion	Histologic Features	Surgical Margins	Immune Status
Low risk	<2 cm	Sun exposed sites (except ear/lip)	<6 mm/invasion above subcutaneous fat	Well-differentiated common variant or verrucous	Clear	Immunocompetent
High risk	>2 cm	Ear/lip Non-sun-exposed sites (sole of foot) SCC arising in radiation sites, scars, burns or chronic inflammatory conditions Recurrent SCCs	>6 mm/invasion beyond subcutaneous fat	Moderately or poorly differentiated grade Acantholytic, spindle, or desmoplastic subtype Perineural invasion	Incomplete excision	Immunosuppressed (organ transplant recipients, chronic immunosuppressive disease or treatment)

Abbreviation: SCC, squamous cell carcinoma.

From Stratigos A, Garbe C, Lebbe C, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. *Eur J Cancer* 2015;51(14):1989–2007; with permission.

are more likely to behave aggressively in terms of local recurrence and increased rate of metastasis.^{89–91}

Recurrence status Not surprisingly, tumor recurrence itself is a high-risk feature.⁸⁸ Recurrent tumors tend to be larger, are more likely to manifest perineural invasion, lymphovascular invasion, subcutaneous invasion, and lymph node metastasis, and are associated with poorer disease-specific survival.^{86,87,92,93}

Number of tumors Multiple cSCC are associated with an increased risk of local recurrence and lymph node metastasis. In 1 study, having more than 1 tumor increased the risk of local recurrence and nodal metastasis by 2- to 4-fold and 3- to 4-fold, respectively.⁹⁴

Immunosuppression Solid organ transplant recipients on immunosuppressive therapy develop aggressive tumors at an increased frequency. This increased incidence is estimated to be as high as 65- to 250-fold as compared with the general population.^{11,95} These tumors also exhibit rapid growth, an increased rate of local recurrence, and metastasis.^{96,97} Thus, the immunosuppressed state is an independent predictor of poor outcomes.⁹⁸

Histopathologic high-risk features

Tumor size Cutaneous SCC tumors with a 2.0-cm or greater maximum diameter are more likely to metastasize.^{79,86} A metaanalysis has shown that a tumor diameter of 2.0 cm or greater is independently predictive of recurrence and metastasis.⁸⁸ The increased recurrence and metastasis rates for an SCC 2.0 cm or greater in size arising on lips and skin were 2-fold and 3.3-fold, respectively, when compared with tumors less than 2.0 cm in size.⁸⁷

Tumor thickness and depth of invasion Tumor thickness and depth of invasion are independent predictors of both local recurrence and metastasis.^{79,88} The American Joint Committee on Cancer and National Comprehensive Cancer Network guidelines consider an invasion depth of 2.0 mm or greater or Clark level IV or higher as the high-risk factor.^{77,84} A corollary of the prognostic significance of the depth of invasion could be that cSCC tumors of identical thickness may show different clinical behavior based on their body location, owing to the varying thickness of dermis and subcutaneous tissue.

Margin status Margin-positive reexcision is recently identified as an independent risk factor for locoregional recurrence, whereas margin-negative reexcision is associated with a low-risk prognosis (29% vs 5% local recurrence). Hence, while evaluating a reexcision specimen, patients with a positive margin should be considered at high risk for recurrence.^{85,99}

Histologic grade Tumor differentiation grade is an independent predictor of recurrence, metastasis, and patient survival.^{79,86,88} Indeed, in 1 study, well-differentiated cSCC showed a local recurrence rate of 13.6%, and a 5-year cure rate of 94.6%, whereas the poorly differentiated cSCC showed a recurrence rate of 28.6% and 5-year cure rate of 61.5%.⁸⁷ A more recent metaanalysis showed that the 5-year metastasis-free and overall survival rates were significantly higher in well-differentiated tumors (70%) as compared with moderately differentiated (51%) and poorly differentiated (26%) tumors.⁸⁸

Histologic subtype Although it is customary to think of several cSCC histologic subtypes as being associated with an aggressive tumor behavior, for the most part, there

are insufficient data in this regard. For example, acantholytic SCC is thought to be highly aggressive, but this is not convincingly supported by published literature.^{47,100} In contrast, desmoplastic SCC or tumors with infiltrative and desmoplastic growth patterns are associated with aggressive behavior in terms of local recurrence and metastasis.^{59,101} The 2016 National Comprehensive Cancer Network Clinical Practice Guidelines for cSCC designates acantholytic, adenosquamous, and desmoplastic SCC subtypes as high-risk factors.⁸⁴ The current European Organization for Research and Treatment of Cancer guidelines list acantholytic, spindle, and desmoplastic subtypes as the high-risk prognostic factors.⁸⁵ KA, when identified with certainty based on clinical and histologic features, is not regarded as a subtype of cSCC and that is borne out by a recent metaanalysis of 445 cases of KA with reported follow-up; none of these cases resulted in death or distant metastases.¹⁰²

Perineural invasion Perineural invasion independently predicts increased rate of local recurrence and metastasis. In particular, perineural invasion of large-caliber nerves (≥ 0.1 mm) is associated with an increased likelihood of lymph node metastasis and higher mortality rate.^{92,103,104} In cSCC of the head and neck region, 1 study found perineural invasion in 14% of all cases, which was associated with increased incidence of cervical lymphadenopathy, distant metastasis, and a significantly reduced survival.¹⁰⁵

Lymphovascular invasion Lymphovascular invasion is an independent predictor of lymph node metastasis^{106,107} and disease-specific death.¹⁰³

Our recommendations for pathology reporting

Based on this discussion of the current evidence and guidelines, we recommend that a pathology report includes a comment on the following features:

- *Tumor size* - particularly when approaching or more than 2 cm
- *Tumor thickness* - particularly when approaching or more than 2 mm
- *Tumor depth* - particularly when approaching or more than Clark level IV
- *Margin status* - particularly in the reexcision specimens
- *Histologic grade* - particularly when poorly differentiated
- *Histologic subtype* - particularly when acantholytic, adenosquamous, spindle cell, or desmoplastic
- *Perineural invasion* - particularly when involving a nerve approaching or greater than 0.1 mm in diameter
- *Lymphovascular invasion*

MOLECULAR PATHOGENESIS

Importance

The high burden of cSCC produces significant morbidity and mortality around the world; therefore, diagnosing and treating cSCC early in its development is crucial and will minimize morbidity and conserve health care resources. Unfortunately, owing to their cosmetic or functional consequences, dermatologic biopsies are often small and superficial, and hence the entire lesion is frequently not available for examination. This often leads to 1 of 3 undesirable consequences: (1) repeat biopsy, which increases health care costs, (2) overdiagnosis, which leads to an unnecessary reexcision, increased morbidity, and an increased health care costs, or (3) underdiagnosis, which results in a missed opportunity to diagnose cSCC early and may result in increased morbidity and mortality. Therefore, identifying the unique molecular alterations associated with cSCC development, and developing assays that use these molecular alterations as markers of malignancy is of paramount importance. Ideally, such

assays would significantly increase the diagnostic yield even with a limited biopsy specimen. Moreover, in regard to cSCC treatment, there is no standard of care beyond complete surgical excision of the lesion, and the therapeutic options for locally advanced and metastatic disease are limited. Consequently, identifying molecular targets and pathways that drive cSCC development is imperative. We provide a brief overview of the current state of knowledge.

Chromosomal Aberrations, Instability, and Epigenetic Changes

Cytogenetic studies in cSCC have revealed a large number of complex allelic alterations such as deletions, insertions, and translocations.¹⁰⁸ The chromosomes most commonly affected include chromosomes 1, 11, 8, 9, 5, 3, and 7. The most frequently rearranged chromosomal sites are pericentromeric, such as 8q10-q11, 1p10-q12, 5p10-q11, 11p15, and 9p10-q10. Recurrent anomalies such as i(1q), i(8q), i(5p), i(1p), i(9p), and i(9q); losses of part of or the entire chromosomes 2, 4, 8, 9, 11, 13, 14, 18, 21, X and Y, and overrepresentation of 1q, chromosome 7, and 8q have been identified as most frequent cytogenetic aberrations.¹⁰⁹ A large-scale genome-wide association study of cSCC has identified 10 single nucleotide polymorphism (SNP) loci, 6 of which encompass pigmentation genes associated with skin cancer risk. These include nonsynonymous SNPs in SLC45A2 gene on chromosome 5p13 and in TYR gene on chromosome 11q14, as well as a functional intronic SNP in IRF4 gene on chromosome 6p25. Three more previously unreported SCC-associated SNPs were identified in HERC2/OCA2 genes at 15q13, DEF8 gene at 16q24, and RALY gene at 20q11.¹¹⁰

A genome-wide SNP microarray analysis showed that well-differentiated cSCCs are a genetically distinct subpopulation among all cSCCs. Extensive loss of heterozygosity were seen at 3p and 9p. Loss of 9p could result in inactivation of protein tyrosine phosphatase delta, proposed as a candidate tumor suppressor gene in cSCC. Protein tyrosine phosphatase delta microdeletions were also demonstrated in a subset of cSCCs. Fragile histidine triad, a recognized tumor suppressor gene on 3p14.2 was proposed as another candidate gene that undergoes inactivation.¹¹¹ Another study demonstrated that there were 2 distinct telomere phenotypes in cSCCs (and AKs), suggesting 2 modes of initiation of chromosomal instability in cSCCs. One of the telomere phenotypes was associated with a higher degree of aberrant p53 and cyclin D1 expression as well as a more complex karyotype.¹¹²

Specific Gene Mutations

A unique aspect of the skin biology is the presence of a high number of cancer driver gene mutations in the histologically normal sun-exposed skin. It has been shown that there are thousands of evolving cellular clones in the aged, sun-exposed, physiologically normal skin with more than one-quarter of cells carrying cancer-causing mutations in genes such as TP53, NOTCH1, NOTCH2, and FAT1.¹¹³ Although this intriguing observation has the potential to provide insights into the early stages of squamous carcinogenesis, it also points to a potential impediment in being able to use these genes as diagnostic or prognostic biomarkers, or therapeutic targets. Another study, despite the high mutational background caused by UV exposure, has identified 23 candidate driver genes in aggressive cSCC that include TP53, CDKN2A, NOTCH1, NOTCH2, AJUBA, HRAS, CASP8, FAT1, KMT2C (MLL3), PARD3, and RASA1.¹¹⁴ We discuss in detail some of the genes frequently found to be mutated in cSCC.

TP53

It has been well-established that a large proportion of cSCC and precursor lesions harbor UV radiation-induced TP53 mutations. These UV signature mutations are found in up to 90% of all cSCC. The fact that TP53 mutations have been found in precursor lesions suggests that this might be an early event in squamous carcinogenesis.^{115–117} However, the increased expression levels of mutant p53 also predict aggressive tumor behavior. One study showed that the IHC scores of p53 protein expression had a strong association with histologic grades and TNM stages of cSCC, with tumors expressing high score of p53 being more aggressive as compared with tumors having low score of p53.¹¹⁸

CDKN2A

Tumor suppressor genes p16INK4a and p14ARF are the alternative reading frames of CDKN2A locus on 9p21, which is frequently deleted in cSCC. Deletion of p16INK4a is thought to correlate with progression from AK to cSCC.^{119,120}

NOTCH

NOTCH is a direct target of p53 that plays a role in the differentiation of epidermal keratinocytes. NOTCH1 is expressed in full thickness of the epidermis, whereas NOTCH2 expression is localized mainly to the basal layer of epidermis. Loss of function NOTCH1 and NOTCH2 mutations are identified in more than 75% of cSCC. NOTCH1 mutation is considered an early event in squamous carcinogenesis of the skin and has been demonstrated to lead to a patchy loss of expression in the normal epidermis.^{117–121} Precise exomic sequencing of UV-exposed epidermis and SCCIS also implicates NOTCH1, NOTCH2 and multiple nulloporins in the early stages of UV-induced carcinogenesis (Seykora and colleagues, unpublished data, 2017).

RAS

The dysregulation of the RAS protooncogene has been implicated in the cSCC initiation in mouse models of chemical carcinogenesis. Recent studies have shown activating mutations of RAS in 12% to 20% of cSCCs.^{122,123} The use of targeted BRAF inhibition in melanoma has led to additional insights into the role of RAS in cSCC. About 25% of patients receiving vemurafenib develop squamoproliferative lesions, including well-differentiated cSCC, which have an increased frequency of gain of function RAS mutations (35%–60%) compared with sporadic cSCC.²⁸

KNSTRN

UV radiation signature mutations in KNSTRN, a kinetochore protein have been detected in 19% of cSCC in 1 study. Point mutations of KNSTRN disrupt sister chromatid cohesion and chromosome segregation, leading to aneuploidy. KNSTRN mutations are also identified in the normal epidermis in addition to AK and cSCC, suggesting that KNSTRN dysregulation can be an early event in squamous carcinogenesis.¹²⁴

p300

Higher expression of the transcriptional coactivator p300 has been found in cSCC compared with the adjacent histologically normal skin. Moreover, high p300 expression has been correlated positively with lymph node metastasis, advanced clinical stage, and poor patient outcomes in terms of recurrence-free survival and overall survival, leading to a suggestion that p300 expression can be a biomarker for predicting clinical outcomes in cSCC patients.¹²⁵

TERT

TERT promoter mutations are frequent in cSCC. Heterogeneity of TERT promoter mutations were found in SCC of different anatomic sites, giving rise to the hypothesis that different tumor development mechanisms are operational in SCC of different sites.^{126,127}

CARD11

In 1 study, CARD11 was found to be mutated in more than 38% of 111 cSCCs. CARD11 regulates nuclear factor κ B signaling cascade and point mutations of CARD11 can lead to constitutive activation of the nuclear factor κ B pathway, which in turn can lead to the transformation of keratinocytes. Consistent with that, CARD11 messenger RNA and protein expression were detectable in normal skin and increased in cSCC. CARD11 mutations are also identified in the peritumoral and sun-exposed skin, suggesting that these mutations may also be early events in tumor development as with TP53, NOTCH1, and KNSTRN.¹²⁸

MicroRNA Alterations

MicroRNAs (miRNA) are small noncoding RNAs that negatively regulate protein expression. Several studies have found that altered expression of miRNAs contribute to the initiation and progression of cSCC. In cSCC, miRNAs that are downregulated include miR1, miR-34a, MiR-124a, miR-125b, miR-155, miR-193b/365a, MiR-199a, MiR-361-5p, and miR-483-3p. The miRNAs that are specifically upregulated in cSCC include miR-21, miR-31, miR-135b, miR205, miR-223, miR-365, miR-424, and miR-766.^{129,130} One study has found significant upregulation of miR-4286, miR-200a-3p, and miR-148-3p, and down-regulation of miR-1915-3p, miR-205-5p, miR-4516, and miR-150-5p in metastatic cSCC as compared with nonmetastatic primary cSCC.¹³¹

SUMMARY

Cutaneous SCC is one of the most common malignancies worldwide, with a trend toward an increasing incidence. It is important to distinguish well-differentiated cSCC from several other benign and reactive squamoproliferative lesions, identify the common histologic variants to avoid diagnostic pitfalls, as well as to detect and report the well-known high-risk histologic features predictive of an aggressive tumor behavior. A better understanding of the molecular pathways that drive the development and progression of cSCC would provide us with new markers for the diagnostic and prognostic assessment, and molecular targets for newer therapeutic modalities.

REFERENCES

1. Elder DE. *Lever's histopathology of the skin*. 10th edition. Philadelphia: Wolters Kluwer/Lippincott Williams & Williams; 2008.
2. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. *J Am Acad Dermatol* 1994;30(5 Pt 1):774-8.
3. Rogers HW, Weinstock MA, Feldman SR, et al. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. Population, 2012. *JAMA Dermatol* 2015;151(10):1081-6.
4. Staples M, Marks R, Giles G. Trends in the incidence of non-melanocytic skin cancer (NMSC) treated in Australia 1985-1995: are primary prevention programs starting to have an effect? *Int J Cancer* 1998;78(2):144-8.

5. Casey AS, Kennedy CE, Goldman GD. Mohs micrographic surgery: how ACMS fellowship directors practice. *Dermatol Surg* 2009;35(5):747–56.
6. Nestor MS, Zarraga MB. The incidence of nonmelanoma skin cancers and actinic keratoses in South Florida. *J Clin Aesthet Dermatol* 2012;5(4):20–4.
7. Karagas MR, Greenberg ER, Spencer SK, et al. Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA. New Hampshire Skin Cancer Study Group. *Int J Cancer* 1999;81(4):555–9.
8. Gray DT, Suman VJ, Su WP, et al. Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. *Arch Dermatol* 1997;133(6):735–40.
9. Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. *J Am Acad Dermatol* 2013;68(6):957–66.
10. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. *J Am Acad Dermatol* 2002;47(1):1–17 [quiz: 18–20].
11. Jensen P, Hansen S, Møller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. *J Am Acad Dermatol* 1999;40(2 Pt 1):177–86.
12. Ramsay HM, Reece SM, Fryer AA, et al. Seven-year prospective study of nonmelanoma skin cancer incidence in U.K. renal transplant recipients. *Transplantation* 2007;84(3):437–9.
13. Silverberg MJ, Leyden W, Warton EM, et al. HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. *J Natl Cancer Inst* 2013;105(5):350–60.
14. Akguner M, Barutçu A, Yilmaz M, et al. Marjolin's ulcer and chronic burn scarring. *J Wound Care* 1998;7(3):121–2.
15. Carli P, Cattaneo A, De Magnis A, et al. Squamous cell carcinoma arising in vulval lichen sclerosis: a longitudinal cohort study. *Eur J Cancer Prev* 1995;4(6):491–5.
16. Jellouli-Elloumi A, Kochbati L, Dhraief S, et al. Cancers arising from burn scars: 62 cases. *Ann Dermatol Venereol* 2003;130(4):413–6 [in French].
17. Knackstedt TJ, Collins LK, Li Z, et al. Squamous cell carcinoma arising in hypertrophic lichen planus: a review and analysis of 38 cases. *Dermatol Surg* 2015;41(12):1411–8.
18. Lavogiez C, Delaporte E, Darras-Vercambre S, et al. Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa. *Dermatology* 2010;220(2):147–53.
19. Sulica VI, Kao GF. Squamous-cell carcinoma of the scalp arising in lesions of discoid lupus erythematosus. *Am J Dermatopathol* 1988;10(2):137–41.
20. Trent JT, Kirsner RS. Wounds and malignancy. *Adv Skin Wound Care* 2003;16(1):31–4.
21. Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. *Arch Dermatol* 1987;123(2):241–50.
22. Kromberg JG, Castle D, Zwane EM, et al. Albinism and skin cancer in Southern Africa. *Clin Genet* 1989;36(1):43–52.
23. Majewski S, Jablonska S. Skin autografts in epidermodysplasia verruciformis: human papillomavirus-associated cutaneous changes need over 20 years for malignant conversion. *Cancer Res* 1997;57(19):4214–6.

24. Gallagher RP, Bajdik CD, Fincham S, et al. Chemical exposures, medical history, and risk of squamous and basal cell carcinoma of the skin. *Cancer Epidemiol Biomarkers Prev* 1996;5(6):419–24.
25. Karagas MR, Stukel TA, Morris JS, et al. Skin cancer risk in relation to toenail arsenic concentrations in a US population-based case-control study. *Am J Epidemiol* 2001;153(6):559–65.
26. Quint KD, Genders RE, de Koning MN, et al. Human beta-papillomavirus infection and keratinocyte carcinomas. *J Pathol* 2015;235(2):342–54.
27. Wang J, Aldabagh B, Yu J, et al. Role of human papillomavirus in cutaneous squamous cell carcinoma: a meta-analysis. *J Am Acad Dermatol* 2014;70(4):621–9.
28. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. *N Engl J Med* 2012;366(3):207–15.
29. Adams CC, Thomas B, Bingham JL. Cutaneous squamous cell carcinoma with perineural invasion: a case report and review of the literature. *Cutis* 2014;93(3):141–4.
30. Hussein MR. Skin cancer in Egypt: a word in your ear. *Cancer Biol Ther* 2005;4(5):593–5.
31. Mora RG, Perniciaro C. Cancer of the skin in blacks. I. A review of 163 black patients with cutaneous squamous cell carcinoma. *J Am Acad Dermatol* 1981;5(5):535–43.
32. Marks R. The role of treatment of actinic keratoses in the prevention of morbidity and mortality due to squamous cell carcinoma. *Arch Dermatol* 1991;127(7):1031–3.
33. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. *Lancet* 1988;1(8589):795–7.
34. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma (“actinic keratosis”). *J Am Acad Dermatol* 2000;42(1 Pt 2):11–7.
35. Stockfleth E. Actinic keratoses. *Cancer Treat Res* 2009;146:227–39.
36. Goldberg LH, Joseph AK, Tschen JA. Proliferative actinic keratosis. *Int J Dermatol* 1994;33(5):341–5.
37. Švajdler M Jr, Mezencev R, Kašpírková J, et al. Human papillomavirus infection and p16 expression in extragenital/extraungual Bowen disease in immunocompromised patients. *Am J Dermatopathol* 2016;38(10):751–7.
38. Al-Arashi MY, Byers HR. Cutaneous clear cell squamous cell carcinoma in situ: clinical, histological and immunohistochemical characterization. *J Cutan Pathol* 2007;34(3):226–33.
39. Memezawa A, Okuyama R, Tagami H, et al. p63 constitutes a useful histochemical marker for differentiation of pagetoid Bowen’s disease from extramammary Paget’s disease. *Acta Derm Venereol* 2008;88(6):619–20.
40. Cassarino DS, Derienzo DP, Barr RJ. Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification—part two. *J Cutan Pathol* 2006;33(4):261–79.
41. Quaedvlieg PJ, Creytens DH, Epping GG, et al. Histopathological characteristics of metastasizing squamous cell carcinoma of the skin and lips. *Histopathology* 2006;49(3):256–64.
42. Cassarino DS, Derienzo DP, Barr RJ. Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification. Part one. *J Cutan Pathol* 2006;33(3):191–206.

43. Driemel O, Müller-Richter UD, Hakim SG, et al. Oral acantholytic squamous cell carcinoma shares clinical and histological features with angiosarcoma. *Head Face Med* 2008;4:17.
44. Johnson WC, Helwig EB. Adenoid squamous cell carcinoma (adenocanthoma). A clinicopathologic study of 155 patients. *Cancer* 1966;19(11):1639–50.
45. Lever WF. Adenocanthoma of sweat glands; carcinoma of sweat glands with glandular and epidermal elements: report of four cases. *Arch Derm Syphilol* 1947;56(2):157–71.
46. Muller SA, Wilhelmj CM Jr, Harrison EG Jr, et al. Adenoid squamous cell carcinoma (adenocanthoma of lever). Report of seven cases and review. *Arch Dermatol* 1964;89:589–97.
47. Ogawa T, Kiuru M, Konia TH, et al. Acantholytic squamous cell carcinoma is usually associated with hair follicles, not acantholytic actinic keratosis, and is not “high risk”: diagnosis, management, and clinical outcomes in a series of 115 cases. *J Am Acad Dermatol* 2017;76(2):327–33.
48. Banks ER, Cooper PH. Adenosquamous carcinoma of the skin: a report of 10 cases. *J Cutan Pathol* 1991;18(4):227–34.
49. Cubilla AL, Ayala MT, Barreto JE, et al. Surface adenosquamous carcinoma of the penis. A report of three cases. *Am J Surg Pathol* 1996;20(2):156–60.
50. Weidner N, Foucar E. Adenosquamous carcinoma of the skin. An aggressive mucin- and gland-forming squamous carcinoma. *Arch Dermatol* 1985;121(6):775–9.
51. Gartrell R, Pauli J, Zonta M. Primary cutaneous mucoepidermoid carcinoma: a case study with a review of the literature. *Int J Surg Pathol* 2015;23(2):161–4.
52. Evans HL, Smith JL. Spindle cell squamous carcinomas and sarcoma-like tumors of the skin: a comparative study of 38 cases. *Cancer* 1980;45(10):2687–97.
53. Silvis NG, Swanson PE, Manivel JC, et al. Spindle-cell and pleomorphic neoplasms of the skin. A clinicopathologic and immunohistochemical study of 30 cases, with emphasis on “atypical fibroxanthomas”. *Am J Dermatopathol* 1988;10(1):9–19.
54. Martin HE, Stewart FW. Spindle cell epidermoid carcinoma. *Am J Cancer Res* 1935;24(2):273–98.
55. Petter G, Haustein UF. Histologic subtyping and malignancy assessment of cutaneous squamous cell carcinoma. *Dermatol Surg* 2000;26(6):521–30.
56. Ha Lan TT, Chen SJ, Arps DP, et al. Expression of the p40 isoform of p63 has high specificity for cutaneous sarcomatoid squamous cell carcinoma. *J Cutan Pathol* 2014;41(11):831–8.
57. Sigel JE, Skacel M, Bergfeld WF, et al. The utility of cytokeratin 5/6 in the recognition of cutaneous spindle cell squamous cell carcinoma. *J Cutan Pathol* 2001;28(10):520–4.
58. Breuninger H, Holzschuh J, Schaumburg Lever G, et al. Desmoplastic squamous epithelial carcinoma of the skin and lower lip. A morphologic entity with great risk of metastasis and recurrence. *Hautarzt* 1998;49(2):104–8 [in German].
59. Breuninger H, Schaumburg-Lever G, Holzschuh J, et al. Desmoplastic squamous cell carcinoma of skin and vermilion surface: a highly malignant subtype of skin cancer. *Cancer* 1997;79(5):915–9.
60. Kuo T. Clear cell carcinoma of the skin. A variant of the squamous cell carcinoma that simulates sebaceous carcinoma. *Am J Surg Pathol* 1980;4(6):573–83.
61. Swanson PE, Marrogi AJ, Williams DJ, et al. Tricholemmal carcinoma: clinicopathologic study of 10 cases. *J Cutan Pathol* 1992;19(2):100–9.

62. Cramer SF, Heggeness LM. Signet-ring squamous cell carcinoma. *Am J Clin Pathol* 1989;91(4):488–91.
63. McKinley E, Valles R, Bang R, et al. Signet-ring squamous cell carcinoma: a case report. *J Cutan Pathol* 1998;25(3):176–81.
64. Bastian BC, Kutzner H, Ts Yen, et al. Signet-ring cell formation in cutaneous neoplasms. *J Am Acad Dermatol* 1999;41(4):606–13.
65. Malviya N, Wickless H. CD30+ primary cutaneous post-transplant lymphoproliferative disorder with signet-ring cell features. *Hematol Rep* 2016;8(2):6433.
66. Jurado I, Saez A, Luelmo J, et al. Pigmented squamous cell carcinoma of the skin: report of two cases and review of the literature. *Am J Dermatopathol* 1998;20(6):578–81.
67. Morgan MB, Lima-Maribona J, Miller RA, et al. Pigmented squamous cell carcinoma of the skin: morphologic and immunohistochemical study of five cases. *J Cutan Pathol* 2000;27(8):381–6.
68. Chapman MS, Quitadamo MJ, Perry AE. Pigmented squamous cell carcinoma. *J Cutan Pathol* 2000;27(2):93–5.
69. Pool SE, Manieei F, Clark WH Jr, et al. Dermal squamo-melanocytic tumor: a unique biphenotypic neoplasm of uncertain biological potential. *Hum Pathol* 1999;30(5):525–9.
70. Aird I, Johnson HD, Lennox B, et al. Epithelioma cuniculatum: a variety of squamous carcinoma peculiar to the foot. *Br J Surg* 1954;42(173):245–50.
71. Schwartz RA. Verrucous carcinoma of the skin and mucosa. *J Am Acad Dermatol* 1995;32(1):1–21 [quiz: 22–4].
72. Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases. *Am J Dermatopathol* 1993;15(4):332–42 [discussion: 343–52].
73. Schwartz RA. Keratoacanthoma. *J Am Acad Dermatol* 1994;30(1):1–19 [quiz: 20–2].
74. Skalova A, Michal M. Patterns of cell proliferation in actinic keratoacanthomas and squamous cell carcinomas of the skin. Immunohistochemical study using the MIB 1 antibody in formalin-fixed paraffin sections. *Am J Dermatopathol* 1995;17(4):332–4.
75. Shah K, Kazlouskaya V, Lal K, et al. Perforating elastic fibers ('elastic fiber trapping') in the differentiation of keratoacanthoma, conventional squamous cell carcinoma and pseudocarcinomatous epithelial hyperplasia. *J Cutan Pathol* 2014;41(2):108–12.
76. Ahmed MM, Moore BA, Schmalbach CE. Utility of head and neck cutaneous squamous cell carcinoma sentinel node biopsy: a systematic review. *Otolaryngol Head Neck Surg* 2014;150(2):180–7.
77. Farasat S, Yu SS, Neel VA, et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. *J Am Acad Dermatol* 2011;64(6):1051–9.
78. Szewczyk M, Pazdrowski J, Golusiński P, et al. Analysis of selected risk factors for nodal metastases in head and neck cutaneous squamous cell carcinoma. *Eur Arch Otorhinolaryngol* 2015;272(10):3007–12.
79. Brantsch KD, Meisner C, Schönfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. *Lancet Oncol* 2008;9(8):713–20.

80. Brougham ND, Dennett ER, Cameron R, et al. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. *J Surg Oncol* 2012;106(7):811–5.
81. Greene FL, Page DL, Fleming ID, et al, editors. *AJCC cancer staging manual*. 6th edition. New York: Springer; 2002.
82. Sobin L, Gospodarowicz M, Wittekind C, editors. *UICC International Union Against Cancer TNM classification of malignant tumors*. 7th edition. West Sussex (United Kingdom): Wiley-Blackwell; 2009.
83. Karia PS, Jambusaria-Pahlajani A, Harrington DP, et al. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma. *J Clin Oncol* 2014;32(4):327–34.
84. Bichakjian CK, Farma JM, Schmults CD, et al. *NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) squamous cell skin cancer*. Fort Washington (PA): National Comprehensive Cancer Network, Inc; 2016.
85. Stratigos A, Garbe C, Lebbe C, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. *Eur J Cancer* 2015;51(14):1989–2007.
86. Cherpelis BS, Marcusen C, Lang PG. Prognostic factors for metastasis in squamous cell carcinoma of the skin. *Dermatol Surg* 2002;28(3):268–73.
87. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. *J Am Acad Dermatol* 1992;26(6):976–90.
88. Thompson AK, Kelley BF, Prokop LJ, et al. Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: a systematic review and meta-analysis. *JAMA Dermatol* 2016;152(4):419–28.
89. Edwards MJ, Hirsch RM, Broadwater JR, et al. Squamous cell carcinoma arising in previously burned or irradiated skin. *Arch Surg* 1989;124(1):115–7.
90. Mullen JT, Feng L, Xing Y, et al. Invasive squamous cell carcinoma of the skin: defining a high-risk group. *Ann Surg Oncol* 2006;13(7):902–9.
91. Ross AS, Schmults CD. Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature. *Dermatol Surg* 2006;32(11):1309–21.
92. Clayman GL, Lee JJ, Holsinger FC, et al. Mortality risk from squamous cell skin cancer. *J Clin Oncol* 2005;23(4):759–65.
93. Krediet JT, Beyer M, Lenz K, et al. Sentinel lymph node biopsy and risk factors for predicting metastasis in cutaneous squamous cell carcinoma. *Br J Dermatol* 2015;172(4):1029–36.
94. Levine DE, Karia PS, Schmults CD. Outcomes of patients with multiple cutaneous squamous cell carcinomas: a 10-year single-institution cohort study. *JAMA Dermatol* 2015;151(11):1220–5.
95. Hartevelt MM, Bavinck JN, Kootte AM, et al. Incidence of skin cancer after renal transplantation in The Netherlands. *Transplantation* 1990;49(3):506–9.
96. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. *N Engl J Med* 2003;348(17):1681–91.
97. Smith KJ, Hamza S, Skelton H. Histologic features in primary cutaneous squamous cell carcinomas in immunocompromised patients focusing on organ transplant patients. *Dermatol Surg* 2004;30(4 Pt 2):634–41.

98. Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. *J Am Acad Dermatol* 2011;65(2):263–79 [quiz: 280].
99. Bovill ES, Banwell PE. Re-excision of incompletely excised cutaneous squamous cell carcinoma: histological findings influence prognosis. *J Plast Reconstr Aesthet Surg* 2012;65(10):1390–5.
100. Garcia C, Crowson AN. Acantholytic squamous cell carcinoma: is it really a more-aggressive tumor? *Dermatol Surg* 2011;37(3):353–6.
101. Salmon PJ, Hussain W, Geisse JK, et al. Sclerosing squamous cell carcinoma of the skin, an underemphasized locally aggressive variant: a 20-year experience. *Dermatol Surg* 2011;37(5):664–70.
102. Savage JA, Maize JC Sr. Keratoacanthoma clinical behavior: a systematic review. *Am J Dermatopathol* 2014;36(5):422–9.
103. Carter JB, Johnson MM, Chua TL, et al. Outcomes of primary cutaneous squamous cell carcinoma with perineural invasion: an 11-year cohort study. *JAMA Dermatol* 2013;149(1):35–41.
104. Ross AS, Whalen FM, Elenitsas R, et al. Diameter of involved nerves predicts outcomes in cutaneous squamous cell carcinoma with perineural invasion: an investigator-blinded retrospective cohort study. *Dermatol Surg* 2009;35(12):1859–66.
105. Goepfert H, Dichtel WJ, Medina JE, et al. Perineural invasion in squamous cell skin carcinoma of the head and neck. *Am J Surg* 1984;148(4):542–7.
106. Moore BA, Weber RS, Prieto V, et al. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. *Laryngoscope* 2005;115(9):1561–7.
107. Peat B, Insull P, Ayers R. Risk stratification for metastasis from cutaneous squamous cell carcinoma of the head and neck. *ANZ J Surg* 2012;82(4):230–3.
108. Asgari MM, Wang W, Ioannidis NM, et al. Identification of susceptibility loci for cutaneous squamous cell carcinoma. *J Invest Dermatol* 2016;136(5):930–7.
109. Purdie KJ, Harwood CA, Gulati A, et al. Single nucleotide polymorphism array analysis defines a specific genetic fingerprint for well-differentiated cutaneous SCCs. *J Invest Dermatol* 2009;129(6):1562–8.
110. Leufke C, Leykauf J, Kronic D, et al. The telomere profile distinguishes two classes of genetically distinct cutaneous squamous cell carcinomas. *Oncogene* 2014;33(27):3506–18.
111. Bolshakov S, Walker CM, Strom SS, et al. p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. *Clin Cancer Res* 2003;9(1):228–34.
112. Kress S, Sutter C, Strickland PT, et al. Carcinogen-specific mutational pattern in the p53 gene in ultraviolet B radiation-induced squamous cell carcinomas of mouse skin. *Cancer Res* 1992;52(22):6400–3.
113. Giglia-Mari G, Sarasin A. TP53 mutations in human skin cancers. *Hum Mutat* 2003;21(3):217–28.
114. Bukhari MH, Niazi S, Chaudhry NA. Relationship of immunohistochemistry scores of altered p53 protein expression in relation to patient's habits and histological grades and stages of squamous cell carcinoma. *J Cutan Pathol* 2009;36(3):342–9.
115. Brown VL, Harwood CA, Crook T, et al. p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma. *J Invest Dermatol* 2004;122(5):1284–92.

116. Gray SE, Kay E, Leader M, et al. Analysis of p16 expression and allelic imbalance/loss of heterozygosity of 9p21 in cutaneous squamous cell carcinomas. *J Cell Mol Med* 2006;10(3):778–88.
117. Okuyama R, Tagami H, Aiba S. Notch signaling: its role in epidermal homeostasis and in the pathogenesis of skin diseases. *J Dermatol Sci* 2008;49(3):187–94.
118. Chin SS, Romano RA, Nagarajan P, et al. Aberrant epidermal differentiation and disrupted DeltaNp63/Notch regulatory axis in Ets1 transgenic mice. *Biol Open* 2013;2(12):1336–45.
119. Ota T, Takekoshi S, Takagi T, et al. Notch signaling may be involved in the abnormal differentiation of epidermal keratinocytes in psoriasis. *Acta Histochem Cytochem* 2014;47(4):175–83.
120. Wang NJ, Sanborn Z, Arnett KL, et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. *Proc Natl Acad Sci U S A* 2011;108(43):17761–6.
121. South AP, Purdie KJ, Watt SA, et al. NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis. *J Invest Dermatol* 2014;134(10):2630–8.
122. Balmain A, Ramsden M, Bowden GT, et al. Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. *Nature* 1984;307(5952):658–60.
123. Durinck S, Ho C, Wang NJ, et al. Temporal dissection of tumorigenesis in primary cancers. *Cancer Discov* 2011;1(2):137–43.
124. Lee CS, Bhaduri A, Mah A, et al. Recurrent point mutations in the kinetochore gene KNSTRN in cutaneous squamous cell carcinoma. *Nat Genet* 2014;46(10):1060–2.
125. Chen MK, Cai MY, Luo RZ, et al. Overexpression of p300 correlates with poor prognosis in patients with cutaneous squamous cell carcinoma. *Br J Dermatol* 2015;172(1):111–9.
126. Cheng KA, Kurtis B, Babayeva S, et al. Heterogeneity of TERT promoter mutations status in squamous cell carcinomas of different anatomical sites. *Ann Diagn Pathol* 2015;19(3):146–8.
127. Griewank KG, Murali R, Schilling B, et al. TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma. *PLoS One* 2013;8(11):e80354.
128. Watt SA, Purdie KJ, den Breems NY, et al. Novel CARD11 mutations in human cutaneous squamous cell carcinoma lead to aberrant NF-kappaB regulation. *Am J Pathol* 2015;185(9):2354–63.
129. Bruegger C, Kempf W, Spoerri I, et al. MicroRNA expression differs in cutaneous squamous cell carcinomas and healthy skin of immunocompetent individuals. *Exp Dermatol* 2013;22(6):426–8.
130. Sand M, Skrygan M, Georgas D, et al. Microarray analysis of microRNA expression in cutaneous squamous cell carcinoma. *J Dermatol Sci* 2012;68(3):119–26.
131. Gillespie J, Skeeles LE, Allain DC, et al. MicroRNA expression profiling in metastatic cutaneous squamous cell carcinoma. *J Eur Acad Dermatol Venereol* 2016;30(6):1043–5.